Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL4124797 | 0.89 | ACHE (0.40) | ACHE | |
| SCHEMBL4128429 | 0.88 | GPR119 (0.42) | TGFBR1GPR119GBA1LMNAKDM4E | |
| SCHEMBL4121133 | 0.87 | GPR119 (0.43) | TGFBR1GPR119GBA1LMNAKDM4E | |
| Dimethylamine SCHEMBL4129628 | 0.86 | GPR119 (0.48) | GPR119KDM4EPKMCSF1RKDR | |
| Dimethylamine SCHEMBL4133492 | 0.85 | LMNA (0.41) | TGFBR1GPR119LMNAKDM4EPKM | |
| SCHEMBL4126897 | 0.85 | GPR119 (0.40) | TGFBR1GPR119GBA1LMNAKDM4E | |
| Dimethylamine SCHEMBL4126791 | 0.85 | TGFBR1 (0.44) | TGFBR1GPR119KDM4EPKMTP53 | |
| Dimethylamine SCHEMBL4120528 | 0.84 | GPR119 (0.45) | GPR119GBA1KDM4EPKMCSF1R | |
| Dimethylamine SCHEMBL4122103 | 0.84 | GPR119 (0.42) | GPR119KDM4EPKMCSF1RKDR | |
| SCHEMBL4126892 | 0.83 | TGFBR1 (0.39) | TGFBR1GPR119GBA1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | TGFBR1 1008/4885GPR119 122/4885GBA1 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.